SCHEMBL20209032

SCHEMBL20209032

CS(=O)(=O)Nc1ccc(C(=O)O)cc1OC(F)(F)F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NEU3 Q9UQ49 1/20 0.51
PYGL P06737 1/20 0.47
AKR1C3 P42330 1/20 0.45
AKR1C2 P52895 1/20 0.45
PTGFR P43088 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
KDM4E B2RXH2 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MTHFD1 P11586 2/20 0.42
MTHFD2 P13995 2/20 0.42
ALDH1A1 P00352 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
CNR2 P34972 1/20 0.41
AURKA O14965 1/20 0.41
ALPL P05186 2/20 0.41
RAD52 P43351 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20209304 0.86 PGR (0.51) PYGLAKR1C3AKR1C2PTGFRKDM4E
SCHEMBL5364834 0.82 SMN1; SMN2 (0.58) NEU3PYGLSMN1; SMN2KDM4EHSD17B10
SCHEMBL20209033 0.80 PYGL (0.49) PYGLAKR1C3AKR1C2PTGFRKDM4E
SCHEMBL16887440 0.80 MRGPRX1 (0.47) SMN1; SMN2KDM4EHSD17B10MEN1KMT2A
SCHEMBL21416879 0.80 PYGL (0.51) PYGLAKR1C3AKR1C2PTGFRKDM4E
SCHEMBL15220190 0.78 IDH1 (0.47) ALDH1A1CNR2ALPLKIF11
SCHEMBL12998566 0.78 PTGS1 (0.61) NEU3AKR1C3SMN1; SMN2KDM4EHSD17B10
SCHEMBL29791247 0.77 NEU3 (0.63) NEU3SMN1; SMN2KDM4EHSD17B10ALDH1A1
SCHEMBL567311 0.77 NEU3 (0.63) NEU3SMN1; SMN2KDM4EHSD17B10ALDH1A1
SCHEMBL24691709 0.77 PYGL (0.47) PYGLAKR1C3AKR1C2PTGFRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3546463-B1 SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON DAIICHI SANKYO CO LTD (JP) 2022-12-07 EP disclosed
EP-3546463-B1 SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON DAIICHI SANKYO CO LTD (JP) 2022-12-07 EP disclosed
US-10774087-B2 Sulfonamide derivative having coumarin skeleton DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-09-15 US disclosed
US-10774087-B2 Sulfonamide derivative having coumarin skeleton DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-09-15 US disclosed
EP-3546463-A1 SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON Daiichi Sankyo Co., Ltd. (JP) 2019-10-02 EP disclosed
EP-3546463-A1 SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON Daiichi Sankyo Co., Ltd. (JP) 2019-10-02 EP disclosed
US-20190284198-A1 SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON DAIICHI SANKYO COMPANY, LIMITED (JP) 2019-09-19 US disclosed
US-20190284198-A1 SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON DAIICHI SANKYO COMPANY, LIMITED (JP) 2019-09-19 US disclosed
WO-2018097162-A1 SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON 第一三共株式会社 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284198-A1 SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON MTHFD1, MTHFD2, DHFR NEU3 4243/4885PYGL 3034/4885AKR1C3 408/4885
US-10774087-B2 Sulfonamide derivative having coumarin skeleton MTHFD1, MTHFD2, DHFR NEU3 4243/4885PYGL 3034/4885AKR1C3 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.